Catalyst
Slingshot members are tracking this event:
Synergy Pharmaceuticals Files New Drug Application for Plecanatide in Chronic Idiopathic Constipation
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SGYP | Community voting in process | |||||
Additional Information
The plecanatide NDA for CIC is supported by positive results from two phase 3 clinical trials which Synergy completed in 2015. If approved, Synergy plans to launch plecanatide with the CIC indication in the first quarter of 2017.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 29, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Nda, Plecanatide, Chronic Idiopathic Constipation
